# Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

> **NCT06053242** · PHASE1,PHASE2 · RECRUITING · sponsor: **Creative Medical Technology Holdings Inc** · enrollment: 45 (estimated)

## Conditions studied

- Chronic Low-back Pain
- Degenerative Disc Disease

## Interventions

- **DRUG:** CELZ-201-DDT
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06053242
- **Lead sponsor:** Creative Medical Technology Holdings Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06053242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06053242, "Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06053242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*